Lataa...
ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody
NK-92 cells, and their derivative, designated aNK, were obtained from a patient with non-Hodgkin lymphoma. Prior clinical studies employing adoptively transferred irradiated aNK cells have provided evidence of clinical benefit and an acceptable safety profile. aNK cells have now been engineered to e...
Tallennettuna:
| Julkaisussa: | Int J Cancer |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5604238/ https://ncbi.nlm.nih.gov/pubmed/28477372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30767 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|